SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pathogenesis(pgns)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Ken M who wrote (63)3/26/1998 11:10:00 PM
From: fossilmark  Read Replies (2) of 228
 
First quarter results will be announced the week of April 20th and it would be great to scoop the street with good research into the early uptake on TOBI.

I'm bullish based on the product and disease fundamentals, and the way the product was developed. I still have a few lingering doubts. Will MDs reserve this for the worst case patients, or will the use it as intended -- a way to prevent infection? Will insurance reimburse? Will generics pose much of a threat?

Does any one out there know anyone with CF or anyone who works in CF (such as a doctor or pharmacists)? How about someone in the distribution channels? Any insight would be great.

Thanks,

Fossilmark
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News